Centauri awarded follow-on CARB-X grant

Centauri Therapeutics Limited, an immunotherapy company focused on the treatment of infectious diseases, has been awarded a grant of up to $2.7 million USD (c.£2 million GBP) from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership dedicated to accelerating antibacterial research to address the rising threat of drug-resistant bacteria. The funding will support the continued development of Centauri’s antimicrobial resistance (AMR) research to identify and advance novel antibacterial candidates through to first-in-human trials.